FibroGen (FGEN) Competitors $10.38 -0.39 (-3.62%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$10.36 -0.02 (-0.14%) As of 10/17/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FGEN vs. IPHA, FTLF, ANRO, CRBP, MCRB, MIST, AVTX, SAVA, ELDN, and PEPGShould you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include Innate Pharma (IPHA), FitLife Brands (FTLF), Alto Neuroscience (ANRO), Corbus Pharmaceuticals (CRBP), Seres Therapeutics (MCRB), Milestone Pharmaceuticals (MIST), Avalo Therapeutics (AVTX), Cassava Sciences (SAVA), Eledon Pharmaceuticals (ELDN), and PepGen (PEPG). These companies are all part of the "pharmaceutical products" industry. FibroGen vs. Its Competitors Innate Pharma FitLife Brands Alto Neuroscience Corbus Pharmaceuticals Seres Therapeutics Milestone Pharmaceuticals Avalo Therapeutics Cassava Sciences Eledon Pharmaceuticals PepGen FibroGen (NASDAQ:FGEN) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings. Which has more volatility & risk, FGEN or IPHA? FibroGen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500. Is FGEN or IPHA more profitable? Innate Pharma has a net margin of 0.00% compared to FibroGen's net margin of -3.86%. Company Net Margins Return on Equity Return on Assets FibroGen-3.86% N/A -27.34% Innate Pharma N/A N/A N/A Which has preferable valuation & earnings, FGEN or IPHA? FibroGen has higher revenue and earnings than Innate Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFibroGen$29.62M1.42-$47.58M-$0.38-27.32Innate Pharma$21.77M9.17-$53.53MN/AN/A Do analysts rate FGEN or IPHA? FibroGen currently has a consensus price target of $43.00, suggesting a potential upside of 314.26%. Innate Pharma has a consensus price target of $6.50, suggesting a potential upside of 200.23%. Given FibroGen's higher possible upside, equities research analysts plainly believe FibroGen is more favorable than Innate Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroGen 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Innate Pharma 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders and institutionals believe in FGEN or IPHA? 72.7% of FibroGen shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 3.1% of FibroGen shares are held by insiders. Comparatively, 31.9% of Innate Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media refer more to FGEN or IPHA? In the previous week, Innate Pharma had 1 more articles in the media than FibroGen. MarketBeat recorded 1 mentions for Innate Pharma and 0 mentions for FibroGen. FibroGen's average media sentiment score of 0.00 equaled Innate Pharma'saverage media sentiment score. Company Overall Sentiment FibroGen Neutral Innate Pharma Neutral SummaryFibroGen and Innate Pharma tied by winning 5 of the 10 factors compared between the two stocks. Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FGEN vs. The Competition Export to ExcelMetricFibroGenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.57M$2.61B$6.10B$10.49BDividend YieldN/A57.79%5.73%4.80%P/E Ratio-27.3222.9985.3827.13Price / Sales1.42561.50520.13179.96Price / CashN/A168.7137.2361.22Price / Book-0.205.3212.236.52Net Income-$47.58M$33.06M$3.33B$276.93M7 Day Performance-1.61%2.29%1.18%1.93%1 Month Performance-8.79%6.32%6.16%2.19%1 Year Performance6.05%-5.42%60.00%35.00% FibroGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FGENFibroGen3.9325 of 5 stars$10.38-3.6%$43.00+314.3%+5.1%$43.57M$29.62M-27.32570Gap UpIPHAInnate Pharma2.0905 of 5 stars$2.01-2.7%$6.50+224.2%+7.7%$189.44M$21.77M0.00220FTLFFitLife Brands3.5611 of 5 stars$19.74-2.0%$23.00+16.5%+11.5%$189.23M$64.47M23.5020ANROAlto Neuroscience1.9297 of 5 stars$6.55-4.9%$9.80+49.6%-57.3%$186.56MN/A-2.74N/ACRBPCorbus Pharmaceuticals4.0435 of 5 stars$14.52-2.1%$45.43+212.9%+3.7%$181.74MN/A-3.0540MCRBSeres Therapeutics2.3824 of 5 stars$21.00+2.0%$14.33-31.7%+12.1%$180.26M$126.32M-4.57330MISTMilestone Pharmaceuticals2.6915 of 5 stars$2.12+0.5%$4.50+112.3%+32.0%$179.34M$1M-2.5230Positive NewsGap UpAVTXAvalo Therapeutics2.9775 of 5 stars$14.00+4.5%$31.67+126.2%+47.6%$176.24M$440K0.0040News CoverageAnalyst ForecastShort Interest ↑SAVACassava Sciences2.4837 of 5 stars$3.57-1.7%$2.00-44.0%-85.5%$175.36MN/A-1.4030ELDNEledon Pharmaceuticals1.8139 of 5 stars$2.86+0.7%$10.00+249.7%+22.4%$170.06MN/A-2.4410News CoverageGap UpPEPGPepGen3.0231 of 5 stars$4.96-3.3%$8.40+69.4%-44.9%$168.26MN/A-1.6830Short Interest ↑ Related Companies and Tools Related Companies Innate Pharma Competitors FitLife Brands Competitors Alto Neuroscience Competitors Corbus Pharmaceuticals Competitors Seres Therapeutics Competitors Milestone Pharmaceuticals Competitors Avalo Therapeutics Competitors Cassava Sciences Competitors Eledon Pharmaceuticals Competitors PepGen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FGEN) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredHoly ****... This could actually MAGAA new document circulating from Washington is stirring major controversy — one that some say could redefine Am...StocksToTrade | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredNvidia CEO’s Regret: ‘I Wish I Gave [Elon] More’…Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FGEN Stock Alerts